EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
Clinical trial NCT06194825 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06194825
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-01
- Primary completion
- 2026-05-13
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.